Search Follow us


In mid-September, Oncology Venture (OV) provided an update on its focused Phase II study investigating LiPlaCis in heavily pre-treated metastatic breast cancer (mBC) patients. To date, 26 patients have been enrolled in the trial via the drug response predictor (DRP) screening programme. Nine patients were segmented into the top one-third of responders and of these, 55% achieved partial remission. Notably, only the top responders as identified by the DRP achieved this, which may suggest that the DRP could prospectively identify responders.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs